Linksbridge Pharma: July 17 highlights
Each week, Linksbridge covers industry and R&D developments important to global health. From early-stage vaccines to multistakeholder initiatives supporting market health, we tell you what’s happening and why it matters. To access full coverage, sign up today.
“Patient-friendly” PKDL regimen succeeds in Phase 2
A new regimen for treating post-kala-azar dermal leishmaniasis (PKDL) is “shorter, safer, and more effective” than the current standard of care, the Drugs for Neglected Diseases Initiative (DNDI) announced Wednesday, citing results from a Phase 2 study.
The Sudan-based trial, conducted primarily in children, found that 98% of participants who received a combination regimen of oral miltefosine with injectable paromomycin achieved a complete cure.
Oxford Marburg vaccine enters Phase 1
Oxford University has launched a U.K.-based first-in-human trial of a Marburg virus vaccine, the university announced last week.
The study will evaluate ChAdOx1 Marburg in 46 people ages 18-55. According to the press release, the research was funded by the British government as part of the U.K. Vaccine Network, an aid program supporting vaccine development for diseases with epidemic potential in LMICs.
领英推荐
J&J dealt new patent setback for TB drug
Indian officials have rejected J&J’s patent application for a pediatric formulation of TB drug bedaquiline.
Celebrating the decision on Wednesday, Médecins Sans Frontières (MSF) called it “a significant step toward increasing affordable access.”
According to MSF, the Indian Patent Office’s ruling stemmed from an MSF-backed pre-grant opposition filed in 2020 by the Delhi Network of Positive People, an advocacy group.
Additional stories from July 17:
A complete preview of this week’s issue is available here.
For full coverage of pharma, vaccines, AMR, and health campaign news, sign up for Linksbridge newsletters today.